GoodRx (GDRX)
(Delayed Data from NSDQ)
$6.88 USD
-0.18 (-2.55%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.89 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.88 USD
-0.18 (-2.55%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.89 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
How Much Upside is Left in GoodRx Holdings, Inc. (GDRX)? Wall Street Analysts Think 27.83%
by Zacks Equity Research
The consensus price target hints at a 27.8% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.
STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.
Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.
Earnings Estimates Rising for GoodRx Holdings, Inc. (GDRX): Will It Gain?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes GoodRx Holdings, Inc. (GDRX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
After Golden Cross, GoodRx Holdings, Inc. (GDRX)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Compared to Estimates, GoodRx Holdings, Inc. (GDRX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.
Avantor, Inc. (AVTR) Q3 Earnings Meet Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 0% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ICLR vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Down -11.5% in 4 Weeks, Here's Why You Should You Buy the Dip in GoodRx Holdings, Inc. (GDRX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for GoodRx Holdings, Inc. (GDRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ICLR vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
ICLR or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Walgreens (WBA) and VillageMD Expand Partnership in Chicago
by Zacks Equity Research
Walgreens (WBA) and VillageMD's coordinated primary care and pharmacy services are now available in Chicago.